Sundar Jagannath, MBBS

The final segment synthesizes the discussion and looks ahead to the future of BCMA bispecifics. Jagannath recaps the extraordinary strides made thus far, from strong response rates to improved safety management, and highlights the growing role of combinations with agents like daratumumab and the expansion into newly diagnosed and smoldering myeloma clinical trials.

Here, the panel turns to one of the most debated questions surrounding bispecific antibodies: how long should patients remain on therapy? Jagannath raises a scenario involving a patient who achieves MRD-negative complete remission after 1 and 2 years of therapy, prompting discussion about whether to continue, taper, or discontinue treatment.

This segment tackles one of the most nuanced decisions in modern myeloma treatment: determining when to use BCMA CAR T-cell therapy versus a BCMA bispecific antibody.

This segment addresses one of the most rapidly evolving challenges in myeloma therapeutics: how to safely transition bispecific-treated patients between academic and community settings.

This segment focuses on the practical, multidisciplinary coordination required to safely administer bispecific antibodies.

Explore the complexities of treating a 72-year-old woman with relapsed refractory multiple myeloma using bispecific antibody therapy.

Explore the latest advancements in bispecific antibodies for treating BCMAs, highlighting their efficacy, administration frequency, and toxicity profiles.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

Experts discuss the rapid advancements in BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma, highlighting improved response rates and treatment integration.